Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 50% less
These brands contain the same active ingredient (Daclatasvir). Same strength and form. Confirm the switch with your doctor or pharmacist.
More from Daclacee
Other strengths and forms by Jenphar Bangladesh Ltd.
Indications & Uses
Dasvir is used together with sofosbuvir to treat long-term (chronic) hepatitis C virus (HCV) infection in adults.
Pharmacology
Daclatasvir is a direct-acting antiviral (DAA) that works against the Hepatitis C Virus (HCV). It blocks NS5A, a nonstructural protein the virus needs to function, by attaching to the N-terminus of this protein. Through this action, Daclatasvir stops the virus from replicating its RNA and from assembling new virus particles.
Studies of Daclatasvir-resistant viruses, along with biochemical research and computer modeling, show that Daclatasvir specifically targets the N-terminus within Domain 1 of NS5A. This interaction appears to distort the protein's structure enough to disrupt its normal functions.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Dosage: The recommended dose of Daclatasvir is 60 mg once daily, taken by mouth with or without food. Daclatasvir must always be given together with other medicines. Before starting treatment with Daclatasvir, the Summary of Product Characteristics for the other medicines in the regimen should also be consulted. The recommended regimens and treatment durations are shown in the table below. For the Daclatasvir plus Sofosbuvir regimen, data on a 12-week treatment duration are available only for treatment-naïve patients with genotype 1 infection. For Daclatasvir plus Sofosbuvir, with or without Ribavirin, data are available for patients with advanced liver disease (≥F3) without cirrhosis. The recommended use of Daclatasvir plus Sofosbuvir in genotype 4 is based on extrapolation from genotype 1. For the Daclatasvir plus Peginterferon alfa plus Ribavirin regimen, data are available for treatment-naïve patients. When Ribavirin is combined with Daclatasvir, its dose is based on body weight (1,000 mg for patients under 75 kg, or 1,200 mg for patients of 75 kg or more). Dose modification, interruption and discontinuation: Changing the dose of Daclatasvir to manage side effects is not recommended. If treatment with any component of the regimen has to be interrupted because of side effects, Daclatasvir must not be continued on its own as monotherapy. There are no virologic stopping rules for the combination of Daclatasvir with Sofosbuvir. Treatment should be discontinued in patients who show an inadequate virologic response while on Daclatasvir, Peginterferon alfa and Ribavirin. Dose recommendation for concomitant medicines: Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): the dose of Daclatasvir should be reduced to 30 mg once daily when given with strong CYP3A4 inhibitors. Moderate inducers of CYP3A4: the dose of Daclatasvir should be increased to 90 mg once daily when given with moderate CYP3A4 inducers. Missed doses: Patients should be told that if they miss a dose of Daclatasvir, it should be taken as soon as possible if remembered within 20 hours of the scheduled time. If the missed dose is remembered more than 20 hours after the scheduled time, it should be skipped and the next dose taken at the usual time.
Side Effects
The following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. A person may experience any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, and memory problems.
Cautions & Contraindications
Warnings & Precautions
Drug interactions with Dasvir can cause adverse reactions or loss of virologic response. Taking Dasvir together with other drugs may lead to known or potentially significant interactions. These may result in loss of Dasvir's therapeutic effect and the possible development of resistance, a need to adjust the dose of Dasvir or the other medications, or possible clinically significant adverse reactions caused by greater exposure to Dasvir or the other drugs. Serious symptomatic bradycardia has occurred when Dasvir is coadministered with Sofosbuvir and Amiodarone, and patients should be counselled about this. Postmarketing cases of symptomatic bradycardia, including cases that required a pacemaker, have been reported when Amiodarone is coadministered with Sofosbuvir in combination with another HCV direct-acting antiviral such as Dasvir. Patients taking Sofosbuvir together with Dasvir who must start Amiodarone because no other treatment option is available should have cardiac monitoring.
Contraindications
Daclatasvir must not be used together with drugs that strongly induce CYP3A, since this may reduce exposure to Daclatasvir and cause loss of efficacy. Contraindicated drugs include, but are not limited to, anticonvulsants (phenytoin, carbamazepine), antimycobacterial agents (rifampin), and herbal products such as St. Jhon’s wort (Hypericum perforatum).
Pregnancy & Breastfeeding
Pregnancy: There isn't enough data on Daclatasvir use in pregnant women to know what risk, if any, it may pose.
Breastfeeding: It isn't known whether Daclatasvir passes into human breast milk, or whether it could affect a breastfed baby or milk supply.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Elderly: Daclatasvir doesn't need a dose adjustment in patients aged ≥65 years.
Renal impairment: No dose adjustment of Daclatasvir is needed for patients with any degree of renal impairment.
Hepatic impairment: Daclatasvir needs no dose adjustment in patients with mild (Child-Pugh A, score 5-6), moderate (Child-Pugh B, score 7-9) or severe (Child-Pugh C, score ≥10) hepatic impairment.
Paediatric population: The safety and efficacy of Daclatasvir in children and adolescents aged below 18 years have not yet been established, and no data are available.
Overdose
There is no known antidote for a Daclatasvir overdose. Treatment is general supportive care, which means monitoring the patient's vital signs and watching their clinical status. Daclatasvir is highly protein bound (>99%), so dialysis is unlikely to lower the plasma concentration of the drug in any significant way.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Daclatasvir at room temperature, below 30°C, and away from light. Keep it out of the reach of children.
Drug Interactions
Common questions about Daclacee 60 mg
What is Daclacee 60 mg Tablet?
Daclacee 60 mg Tablet is a medicine that contains Daclatasvir. It is made by Jenphar Bangladesh Ltd. It belongs to the Hepatic viral infections (Hepatitis C) group of medicines.
What is Daclacee used for?
Dasvir is used together with sofosbuvir to treat long-term (chronic) hepatitis C virus (HCV) infection in adults.
What are the side effects of Daclacee?
The following serious adverse reactions are described below and elsewhere in the labeling: serious symptomatic bradycardia when coadministered with sofosbuvir and amiodarone. A person may experience any of the following symptoms: fainting or near-fainting, dizziness or lightheadedness, not feeling well, weakness, tiredness, shortness of breath, chest pain, confusion, and memory problems.
Can I take Daclacee during pregnancy or while breastfeeding?
Pregnancy: There isn't enough data on Daclatasvir use in pregnant women to know what risk, if any, it may pose. Breastfeeding: It isn't known whether Daclatasvir passes into human breast milk, or whether it could affect a breastfed baby or milk supply. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Daclacee?
There is no known antidote for a Daclatasvir overdose. Treatment is general supportive care, which means monitoring the patient's vital signs and watching their clinical status. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Daclacee?
Keep Daclatasvir at room temperature, below 30°C, and away from light. Keep it out of the reach of children.
Can I take other medicines with Daclacee?
Some medicines can interact with Daclatasvir, for example: Clarithromycin, Itraconazole, Ritonavir, Ketoconazole. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
G-Daclatasvir by Gonoshasthaya Pharmaceuticals Ltd. has the same ingredient and strength for ৳200.00 per unit, compared with ৳400.00 for Daclacee. Ask your doctor or pharmacist before switching.
Do I need a prescription for Daclacee?
Daclacee is a prescription (Rx) medicine. Take it as your doctor advises.